NanoViricides, Inc. (NNVC)
NYSEAMERICAN: NNVC · Real-Time Price · USD
1.400
+0.010 (0.72%)
Oct 23, 2026, 4:00 PM EDT - Market closed
NanoViricides Employees
NanoViricides had 7 employees as of June 30, 2026. The number of employees did not change compared to the previous year. That makes NanoViricides the 41,185th largest employer in the world and 6,280th in the United States.
Employees
7
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,174,073
Market Cap
35.74M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 7 | 0 | - |
| Jun 30, 2025 | 7 | 0 | - |
| Jun 30, 2024 | 7 | 0 | - |
| Jun 30, 2023 | 7 | -10 | -58.82% |
| Jun 30, 2022 | 17 | 0 | - |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| EyePoint | 214 |
| Celularity | 115 |
| IRulya Therapeutics | 38 |
| eXoZymes | 32 |
| Edesa Biotech | 17 |
| Instil Bio | 17 |
| CervoMed | 15 |
| Dogwood Therapeutics | 8 |
NNVC News
- 4 days ago - NanoViricides says NV-387 demonstrates ‘strong’ parameters in animal model study - TheFly
- 4 days ago - NanoViricides' Revolutionary Broad-Spectrum Drug Candidate NV-387 Has Successfully Demonstrated Excellent Indications for Safety and Toxicology in a Juvenile Mouse Pups Animal Study, Paving the Way for Pediatric Use in Clinical Trials - Accesswire
- 11 days ago - NanoViricides announces Phase IIA Ebola trial of NV-387 is progressing well - TheFly
- 11 days ago - Phase II Clinical Trial of NV-387 Oral Gummies as Treatment of Ebola Progressing Well, Says NanoViricides - Accesswire
- 18 days ago - NanoViricides Presenting at NIBA's 153rd Investment Conference in Fort Lauderdale, FL October 7, 2026 - Accesswire
- 19 days ago - NanoViricides says Phase II trial of NV-387 in ebola ‘proceeding as designed’ - TheFly
- 19 days ago - NanoViricides Provides Additional Details on the Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola as the Outbreak Continues to Expand and Has Taken Over 4,000 Lives - Accesswire
- 25 days ago - NanoViricides ‘actively exploring’ additional required funding - TheFly